|
Algorithm features
|
Algorithm 1: plasma Hyp and GSP, G-H1, MG-H1, 3DG-H, CEL, CMA, MetSO, 3-NT, NFK, and DT free adducts
|
Algorithm 2: anti-CCP-Ab positivity assessment and plasma GSP, FL, 3DG-H, CML, CEL, MetSO, and 3-NT free adducts
|
|---|
|
Classification
|
Disease vs control
|
eOA vs non-RA and eRA
|
eRA vs non-RA and eOA
|
Non-RA vs eRA and eOA
|
|
Accuracy (%)
|
88.4 (86.9–90.0)
|
95.5 (93.7–97.3)
|
78.1 (74.3–82.0)
|
78.9 (74.7–83.2)
|
|
Sensitivity (%)
|
90.4 (88.7–92.1)
|
94.0 (88.8–99.3)
|
69.1 (54.4–83.7)
|
67.5 (46.2–88.8)
|
|
Specificity (%)
|
83.2 (77.4–89.0)
|
96.1 (92.6–99.6)
|
83.2 (71.8–94.6)
|
84.6 (77.1–92.1)
|
|
AUROC
|
0.93 (0.92–0.94)
|
0.98 (0.97–0.99)
|
0.86 (0.81–0.90)
|
0.88 (0.86–0.90)
|
|
Positive likelihood ratio
|
8.26 (5.77–10.75)
|
16.11 (9.56–22.66)
|
7.66 (2.94–12.37)
|
4.96 (3.31–6.60)
|
|
Negative likelihood ratio
|
0.11 (0.10–0.13)
|
0.06 (0.01–0.11)
|
0.34 (0.20–0.48)
|
0.36 (0.14–0.57)
|
|
Positive predictive value (%)
|
93.6 (91.7–95.6)
|
92.8 (86.5–99.0)
|
76.3 (65.1–87.4)
|
71.8 (62.7–80.8)
|
|
Negative predictive value (%)
|
77.3 (74.4–80.2)
|
97.5 (95.3–99.6)
|
84.4 (79.0–89.8)
|
86.2 (78.9–93.4)
|
|
F-score
|
0.92 (0.91–0.93)
|
0.93 (0.90–0.96)
|
0.69 (0.62–0.75)
|
0.64 (0.49–0.79)
|
- Abbreviations: MetSO Methionine sulfoxide, FL Nε-fructosyl-lysine, G-H1 Glyoxal-derived hydroimidazolone, MG-H1 Methylglyoxal-derived hydroimidazolone, CMA Nω-carboxymethylarginine, 3DG-H 3-Deoxyglucosone-derived hydroimidazolone isomers, GSP Glucosepane, NFK N-formylkynurenine, 3-NT 3-Nitrotyrosine, Hyp Hydroxyproline, eOA Early-stage osteoarthritis, TKR Total knee replacement, RA Rheumatoid arthritis, eRA Early-stage rheumatoid arthritis, DT Dityrosine, CCP Cyclic citrullinated peptide, CML Nε-carboxymethyl-lysine, CEL Nε-carboxyethyl-lysine
- Data are mean (95% CI). Analyte data other than GSP (Table 2) employed in algorithm development were reported previously [5]
